Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 195,400 shares, a growth of 8.9% from the March 15th total of 179,500 shares. Based on an average daily volume of 671,800 shares, the short-interest ratio is presently 0.3 days.
Cidara Therapeutics Stock Performance
Shares of CDTX opened at $0.73 on Wednesday. Cidara Therapeutics has a 52 week low of $0.59 and a 52 week high of $1.48. The firm has a market cap of $66.15 million, a P/E ratio of -1.87 and a beta of 0.98. The firm’s 50-day simple moving average is $0.78 and its 200 day simple moving average is $0.78.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Cidara Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,346,260 shares of the biotechnology company’s stock valued at $2,657,000 after purchasing an additional 54,310 shares during the period. Renaissance Technologies LLC boosted its holdings in Cidara Therapeutics by 23.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,549,573 shares of the biotechnology company’s stock valued at $1,751,000 after purchasing an additional 292,800 shares during the period. BlackRock Inc. boosted its holdings in Cidara Therapeutics by 29.7% in the 2nd quarter. BlackRock Inc. now owns 961,718 shares of the biotechnology company’s stock valued at $1,087,000 after purchasing an additional 220,005 shares during the period. Geode Capital Management LLC boosted its holdings in Cidara Therapeutics by 10.3% in the 2nd quarter. Geode Capital Management LLC now owns 727,710 shares of the biotechnology company’s stock valued at $822,000 after purchasing an additional 68,043 shares during the period. Finally, Millennium Management LLC boosted its holdings in Cidara Therapeutics by 724.1% in the 4th quarter. Millennium Management LLC now owns 689,917 shares of the biotechnology company’s stock valued at $522,000 after purchasing an additional 606,201 shares during the period. Institutional investors and hedge funds own 35.82% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Report on Cidara Therapeutics
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Read More
- Five stocks we like better than Cidara Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- Silicon Motion Proves That AI in Motion Stays in Motion
- How to invest in marijuana stocks in 7 steps
- Undervalued UnitedHealth Group Won’t Be For Long
- Stock Sentiment Analysis: How it Works
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.